NVCN - Neovasc Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.47
-0.08 (-5.16%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.55
Open1.53
Bid1.11 x 100
Ask1.48 x 300
Day's Range1.46 - 1.55
52 Week Range0.46 - 3.34
Volume117,622
Avg. Volume346,761
Market Cap115.36M
Beta0.73
PE Ratio (TTM)-21.00
EPS (TTM)-0.07
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • Dilution Ahead For Neovasc Inc (TSX:NVCN) Shareholders?
    Simply Wall St.17 days ago

    Dilution Ahead For Neovasc Inc (TSX:NVCN) Shareholders?

    Neovasc Inc (TSX:NVCN) continues its loss-making streak, announcing a -$5.11M earnings for its latest financial year ending. Cash is crucial to run a business, and if a company burns throughRead More...

  • Why You Need To Look At This Factor Before Buying Neovasc Inc (TSX:NVCN)
    Simply Wall St.last month

    Why You Need To Look At This Factor Before Buying Neovasc Inc (TSX:NVCN)

    If you are looking to invest in Neovasc Inc’s (TSX:NVCN), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...

  • CNW Grouplast month

    Neovasc Provides Tiara™ Clinical Update

    Neovasc Provides Tiara™ Clinical Update

  • PR Newswirelast month

    Neovasc Provides Tiara™ Clinical Update

    VANCOUVER, Sept. 12, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today provided an update on the study progress and clinical performance of the TiaraTM valve, a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation ("MR"), one of the most prevalent valvular heart diseases in western countries.  MR is often severe and can lead to heart failure and death.

  • CNW Group2 months ago

    Neovasc's Reducer System Reviewed in European Heart Journal

    Neovasc's Reducer System Reviewed in European Heart Journal

  • PR Newswire2 months ago

    Neovasc's Reducer System Reviewed in European Heart Journal

    VANCOUVER, Sept. 5, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced the European Heart Journal published a clinical review of its Neovasc Reducer™ ("Reducer") device for the treatment of refractory/persistent angina pectoris, a common and disabling medical condition, and a major public health problem that affects millions of patients worldwide.  The European Heart Journal is the official general cardiology journal of the European Society of Cardiology. Refractory angina is a common and disabling clinical condition, and a major public health problem, which affects patients' quality of life, and has a significant impact upon health care resources.  Persistent angina is common not only in patients who are not good candidates for revascularization, but also in patients following successful revascularization.

  • PR Newswire2 months ago

    Decision from Appeals Court upholds lower court decisions but denies injunction

    The Company also sells a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws regarding the Company's plans and expectations concerning its litigation with CardiAQ.

  • CNW Group2 months ago

    Decision from Appeals Court upholds lower court decisions but denies injunction

    Decision from Appeals Court upholds lower court decisions but denies injunction

  • Newsfile2 months ago

    IIROC Trade Halt - Neovasc Inc.

    Toronto, Ontario--(Newsfile Corp. - September 1, 2017) - The following issues have been halted by IIROC: Company:  Neovasc Inc. TSX Symbol: NVCN (all issues) ...

  • Neovasc, Inc. :NVCN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
    Capital Cube2 months ago

    Neovasc, Inc. :NVCN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017

    Categories: Yahoo FinanceGet free summary analysis Neovasc, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Neovasc, Inc. – Novadaq Technologies Inc. and Covalon Technologies Ltd. (NVDQ-US and COV-CA) that have also reported for this period. Highlights Summary numbers: Revenues of USD 1.31 million, Net ... Read more (Read more...)

  • Associated Press2 months ago

    Neovasc reports 2Q loss

    On a per-share basis, the Richmond, British Columbia-based company said it had a loss of 7 cents. Losses, adjusted for non-recurring costs, were 4 cents per share. The medical device company posted revenue ...

  • CNW Group2 months ago

    Neovasc Announces Results for the Second Quarter of 2017

    Neovasc Announces Results for the Second Quarter of 2017

  • PR Newswire2 months ago

    Neovasc Announces Results for the Second Quarter of 2017

    NASDAQ, TSX: NVCN VANCOUVER , Aug. 10, 2017 /PRNewswire/ - Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ, TSX: NVCN) today announced financial results for the second quarter ...

  • CNW Group3 months ago

    Neovasc to Host Second Quarter 2017 Conference Call

    Neovasc to Host Second Quarter 2017 Conference Call

  • PR Newswire3 months ago

    Neovasc to Host Second Quarter 2017 Conference Call

    NASDAQ, TSX: NVCN VANCOUVER , Aug. 3, 2017 /PRNewswire/ -  Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ, TSX: NVCN) today announced that it will release its financial results ...

  • Market Realist4 months ago

    Edwards Lifesciences Wins a Patent Case against Neovasc

    On June 16, 2017, a German court awarded "co-entitlement" rights to Edwards Lifesciences' (EW) subsidiary CardiAQ valve to the Tiara European patent application of Neovasc.

  • PR Newswire4 months ago

    Neovasc Announces German Court Ruling

    VANCOUVER, June 16, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) reported today that the District Court in Munich, Germany has partially found in favour of Edwards Lifesciences Corporation (formerly CardiAQ Valve Technologies Inc.) ("CardiAQ"), in its case against Neovasc.  In this case, CardiAQ had claimed ownership rights to one of Neovasc's European patent applications for its Tiara™ mitral valve replacement technology. The German court found CardiAQ had contributed in part to the invention of the Tiara™ and awarded to CardiAQ co-entitlement rights to the disputed Tiara™ European patent application.  There are no monetary awards associated with this matter.  Neovasc intends to appeal this decision. In a related matter, Neovasc is currently appealing the 2016 decision from the U.S District Court for the District of Massachusetts which among other things granted co-inventorship rights to CardiAQ on one of Neovasc's granted U.S. patent applications.  This appeal is now before the United States Court of Appeals for the Federal Circuit in Washington D.C.  An expedited appeal schedule has been set with all the briefings from both parties now submitted.

  • CNW Group4 months ago

    Neovasc Announces German Court Ruling

    Neovasc Announces German Court Ruling

  • PR Newswire4 months ago

    Neovasc Tiara™ Featured in TVT 2017 Presentation

    VANCOUVER, June 15, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced its Tiara™ technology, developed to treat severe Mitral Regurgitation (MR), is being featured in a video recorded procedure to be presented at the 10th Annual Transcatheter Valve Therapies (TVT) Conference.  TVT is being held from June 14th - 17th, 2017 in Chicago, Illinois.

  • CNW Group4 months ago

    Neovasc Tiara™ Featured in TVT 2017 Presentation

    Neovasc Tiara™ Featured in TVT 2017 Presentation

  • PR Newswire4 months ago

    Neovasc Inc. Reports Results of Annual General Meeting of Shareholders

    NASDAQ, TSX: NVCN VANCOUVER, June 13, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered ...

  • CNW Group4 months ago

    Neovasc Inc. Reports Results of Annual General Meeting of Shareholders

    Neovasc Inc. Reports Results of Annual General Meeting of Shareholders

  • PR Newswire4 months ago

    Neovasc to Present at JMP Securities Life Sciences Conference

    VANCOUVER, June 12, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) a specialty medical device company today announced that Alexei Marko, chief executive officer is scheduled to present at the JMP Securities Life Sciences Conference being held at the St. Regis Hotel in New York City on Wednesday, June 21, 2017, at 9:30 am ET. A live audio webcast of the presentation will be available on the Investors page of Neovasc's website at www.neovasc.com.

  • CNW Group4 months ago

    Neovasc to Present at JMP Securities Life Sciences Conference

    Neovasc to Present at JMP Securities Life Sciences Conference

  • Neovasc, Inc. :NVCN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
    Capital Cube5 months ago

    Neovasc, Inc. :NVCN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017

    Categories: Yahoo FinanceGet free summary analysis Neovasc, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Neovasc, Inc. – Covalon Technologies Ltd. and Novadaq Technologies Inc. (COV-CA and NDQ-CA) that have also reported for this period. Highlights Summary numbers: Revenues of USD 1.48 million, Net ... Read more (Read more...)